NBIX · Categories · Downgrades
NBIX - Analyst downgrades
Neurocrine Biosciences Inc. (NBIX) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for NBIX
- Neurocrine Biosciences downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Neurocrine Biosciences from Overweight to Equal-Weight and set a new price target of $175.00
- Neurocrine Biosciences downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Neurocrine Biosciences from Outperform to In-line and set a new price target of $130.00 from $140.00 previously
- Neurocrine Biosciences downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Neurocrine Biosciences from Overweight to Neutral and set a new price target of $94.00 from $114.00 previously
- Neurocrine Biosciences downgraded by RBC Capital with a new price targetRBC Capital downgraded Neurocrine Biosciences from Outperform to Sector Perform and set a new price target of $90.00 from $122.00 previously
- Neurocrine Biosciences downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Neurocrine Biosciences from Overweight to Equal-Weight and set a new price target of $112.00
- Neurocrine Biosciences downgraded by Canaccord Genuity with a new price targetCanaccord Genuity downgraded Neurocrine Biosciences from Buy to Hold and set a new price target of $108.00 from $122.00 previously
- Neurocrine Biosci downgraded by Canaccord GenuityCanaccord Genuity downgraded Neurocrine Biosci from Buy to Hold